La cadena de opciones muestra datos clave de las opciones de acciones de Moderna a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Moderna..

Moderna (NASDAQ:MRNA) Bolsa, Cadena de Opciones

Moderna

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna Inc

MODERNA ORD

On Thursday,&nbsp;Moderna Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) stock is trading higher after the company reported better-than-<a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41797218/moderna-gears-up-for-q3-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-" rel="noreferrer noopener">expected third-quarter sales</a>.
Moderna reported third-quarter revenue of $1.83 billion, compared with $1.83 billion a year earlier, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.25 billion</a>.
The company attributed the growth to higher sales in the U.S. market following the earlier launch of the updated COVID-19 vaccine.
With FDA approval granted three weeks earlier than in the previous year, the company was able to meet <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40514864/fda-approves-updated-covid-vaccines-from-pfizer-and-moderna-but-leaves-out-novavaxs-shot" rel="noreferrer noopener">demand more effectively</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40348867/struggling-covid-19-vaccines-from-astrazeneca-biontechpfizer-moderna-cut-incidence-of-arterial-th" rel="noreferrer noopener">Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows</a>
Moderna reported $1.8&nbsp;billion in Spikevax sales in the third quarter of 2024, which includes $1.2&nbsp;billion in U.S. sales and $0.6&nbsp;billion in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/ac41801803/moderna-reports-third-quarter-2024-financial-results-and-provides-business-updates" rel="noreferrer noopener">international sales</a>.
Earnings per share was $0.03, compared to a loss per share of $(9.53) for the third quarter of 2023, compared to a consensus loss of $(1.90).
"During the third quarter, we focused on execution with the launch of our updated COVID-19 and RSV vaccines in markets across the globe. I am pleased with the cost efficiency we achieved in the quarter, tracking ahead of where we planned to be at this time," said Stéphane Bancel, Chief Executive Officer of Moderna. "Looking into the fourth quarter and preparing for 2025, we remain focused on driving sales growth, delivering 10 product approvals over the next three years, and continuing to reduce our cost structure."
The company reported $10&nbsp;million in mRESVIA (RSV vaccine) sales in the third quarter of 2024. Sales were lower than anticipated, resulting from the approval and recommendation of mRESVIA later in the contracting season when many customers had completed their orders.
Guidance: Moderna has reiterated its 2024 expected net product sales of $3.0 billion-$3.5 billion from <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40104375/moderna-stock-sinks-on-lowered-2024-outlook-cites-low-european-sales-competitive-rsv-vaccine-mark" rel="noreferrer noopener">its respiratory franchise</a>.
The company expects the cost of sales to be 40-45% of product sales for the year (previously 40-50%), with R&amp;D expenses anticipated to be $4.6 billion—$4.7 billion (previously $4.8 billion).
Moderna intends to file in 2024 for approval of its next-generation COVID-19 vaccine (mRNA-1283) and RSV vaccine (mRNA-1345) for high-risk adults aged 18-59 years.
Price Action: MRNA stock is up 7.04% at $55.46 during the premarket session at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41806970/hersheys-q3-earnings-sour-as-sales-dip-and-outlook-darkens-ceo-pledges-aggressive-turnaround-amid-h" target="_blank" rel="noreferrer noopener">Hershey's Q3 Earnings Sour As Sales Dip And Outlook Darkens; CEO Pledges Aggressive Turnaround Amid High Cocoa Costs</a></li>
</ul>
Photo via <a href="https://commons.wikimedia.org/wiki/File:Moderna_COVID-19_vaccine_%282021%29_F.jpg">Wikimedia Commons</a>

Biotech

Earnings

News

Guidance

Health Care

Movers

Trading Ideas

General

MRNA

Moderna Q3 Revenue Beats On Updated COVID-19 Vaccine, Slashes Expenses For 2024

WIIM

Moderna shares are trading higher after the company reported better-than-expected Q3 sales results.

2024 Financial Framework
<ul>
<li>Net Sales: The Company reiterates its 2024 expected net product sales of $3.0 to $3.5 billion from its respiratory franchise.</li>
<li>Cost of Sales: Cost of sales is now expected to be in the range of 40-45% of product sales for the year (previously 40-50%).</li>
<li>Research and Development Expenses: Full-year 2024 research and development expenses are now anticipated to be in the range of $4.6 to $4.7 billion (previously $4.8 billion).</li>
<li>Selling, General and Administrative Expenses: Selling, general and administrative expenses for 2024 are projected to be approximately $1.2 billion.</li>
<li>Income Taxes: The Company continues to expect its full-year tax expense to be negligible.</li>
<li>Capital Expenditures: Capital expenditures for 2024 are now expected to be approximately $1.2 billion (previously ~$0.9 billion). The updated estimate includes the purchase of the Norwood, MA, campus for ~$0.4 billion.</li>
<li>Cash and Investments: Year-end cash and investments for 2024 are projected to be approximately $9 billion.</li>
</ul>

Moderna Reiterates Its 2024 Expected Net Product Sales Of $3.0B-$3.5B From Its Respiratory Franchise

Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(1.90) by 101.58 percent. The company reported quarterly sales of $1.86 billion which beat the analyst consensus estimate of $1.25 billion by 48.94 percent. This is a 1.69 percent increase over sales of $1.83 billion the same period last year.

Moderna Q3 2024 GAAP EPS $0.03 May Not Be Comparable To $(1.90) Estimate, Sales $1.86B Beat $1.25B Estimate

Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) will release earnings results for its third quarter, before the <a href="https://www.benzinga.com/quote/MRNA/earnings">opening bell on Thursday, Nov. 7.</a>
Analysts expect the Cambridge, Massachusetts-based company to report a quarterly loss at $1.9 per share, versus a year-ago loss of $9.53 per share. Moderna projects to report revenue of $1.25 billion for the quarter, compared to $1.83 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Oct. 28, On Monday, Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and Moderna announced the initiation of INTerpath-009, a pivotal Phase 3 trial of V940 (mRNA-4157).
Moderna shares fell 2.8% to close at $51.81 on Wednesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/TJX/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>JP Morgan analyst Jessica Fye maintained an Underweight rating and cut the price target from $70 to $59 on Oct. 4. This analyst has an accuracy rate of 61%.</li>
<li>Jefferies analyst Michael Yee maintained a Hold rating and slashed the price target from $65 to $55 on Oct. 15. This analyst has an accuracy rate of 63%.</li>
<li>B of A Securities analyst Geoff Meacham maintained a Neutral rating and cut the price target from $130 to $110 on Sept. 13. This analyst has an accuracy rate of 60%.</li>
<li>Needham analyst Joseph Stringer reiterated a Hold rating on Sept. 13. This analyst has an accuracy rate of 77%.</li>
<li>Evercore ISI Group analyst Cory Kasimov maintained an In-Line rating with a price target of $120 on June 27. This analyst has an accuracy rate of 70%.</li>
</ul>
Considering buying MRNA stock? Here&#8217;s what analysts think:
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom">Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom</a></li>
</ul>

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Moderna Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

On Wednesday, Ark Invest, led by Cathie Wood, made significant trades in Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) and Square Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>).
The Moderna Trade
Ark Invest removed 49,922 shares of Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) from its ARK Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) on Wednesday. The trade is estimated to be worth $2.6 million, based on the latest closing price of $51.81.
This move comes after Ark Invest sold a significant amount of Moderna stock earlier in October. The company&#8217;s decision to offload over $9 million in Moderna came amidst the unveiling of Moderna&#8217;s <a href="https://www.benzinga.com/markets/24/10/41300903/cathie-woods-ark-invest-dumps-over-9m-in-moderna-stock-even-with-post-covid-plans-on-the-table">post-COVID roadmap</a>.
The Block Trade
Ark Invest sold 31,771 shares of Block on Wednesday. The trade, made through ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) and Ark Fintech Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>), is estimated to be worth $2.5 million, based on the latest closing price of $77.64.
Jack Dorsey, the CEO of Block, recently announced a fresh <a href="https://www.benzinga.com/news/24/10/41646193/block-ceo-jack-dorsey-announces-another-round-of-layoffs-at-tidal">wave of layoffs</a> at the music streaming service Tidal, which the Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)-focussed Block owns. This move came amidst a significant round of layoffs, with Dorsey stating that Tidal needs to function "like a startup again," necessitating a much smaller team across the organization.
Other Key Trades: 
<ul>
<li>Ark loaded up on shares of Crisper Therapeutics (CRSP) and Twist Bioscience Corp (TWST)</li>
<li>The Wood-led firm sold shares of Sofi Technologies (SOFI) and Unity Software (U). </li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41767332/trumps-potential-return-to-white-house-sends-ex-president-linked-phunware-stock-upwards-during-p?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump&#8217;s Potential Return To White House Sends Ex-President Linked Phunware Stock Upwards During Pre-Market Hours</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Equities

ETFs

$BTC

ARKF

ARKG

ARKK

Cathie Wood's Wednesday Exodus: Moderna And Jack Dorsey's Block Stocks Get Dumped

Robert Kennedy Jr. has disclosed President-Elect Donald Trump&#8217;s three-fold directive to him, aimed at transforming the nation&#8217;s health landscape.
What Happened: On Wednesday, Kennedy Jr. took to X to share the tasks Trump has assigned to him. He wrote that Trump asked him to do three things: clean up corruption in health agencies, restore evidence-based science, and end the chronic disease epidemic to make America healthy again.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">President Trump has asked me to do three things: 1. Clean up the corruption in our government health agencies. 2. Return those agencies to their rich tradition of gold-standard, evidence-based science. 3. Make America Healthy Again by ending the chronic disease epidemic. <a href="https://t.co/WHMOsD0CiI">pic.twitter.com/WHMOsD0CiI</a>
&mdash; Robert F. Kennedy Jr (@RobertKennedyJr) <a href="https://twitter.com/RobertKennedyJr/status/1854281809464529384?ref_src=twsrc%5Etfw">November 6, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/news/large-cap/24/11/41741814/walgreens-agrees-to-100-million-settlement-over-alleged-deceptive-pricing-of-generic-drugs?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Walgreens Agrees To $100 Million Settlement Over Alleged Deceptive Pricing Of Generic Drugs</a>
This announcement comes after Trump&#8217;s previous pledge to give Kennedy <a href="https://www.benzinga.com/news/24/10/41565423/trump-says-robert-kennedy-jr-can-run-wild-on-health-and-food-im-going-to-let-him-go-wild-on-the-medi">full authority over health</a>, food, and medicine issues if he secures a second term. The former President had expressed his intent to allow Kennedy to &#8220;run wild&#8221; on these matters, with the exception of oil.
Kennedy Jr. is known for his contentious views on vaccines and has also been know to speak out regularly on food additives. In the aftermath of the election, shares of pharmaceutical companies, particularly those associated with the COVID-19 vaccine, have slid.
On Wednesday Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Modern Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) stocks hovered near their 52-week lows of $25.20 and $49.60 respectively. For the day, PFE ended 2.2% lower at $27.36, while MRNA dropped 2.8% to $51.81. The iShares U.S. Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>) fell 0.5% to $68.39 in a similar period.
Why It Matters: Kennedy&#8217;s new role and the tasks assigned to him align with Trump&#8217;s earlier statements. In a recent interview, Trump showed tentative support for Kennedy&#8217;s plan to <a href="https://www.benzinga.com/news/24/11/41704387/robert-kennedy-jr-says-he-will-advise-all-us-water-systems-to-remove-fluoride-on-day-1-of-trump-admi">remove fluoride from water</a>, a move aimed at improving public health. Kennedy, known for his health-related advocacies, stated that his administration would encourage all U.S. water systems to eliminate fluoride on its first day in office.
Furthermore, Kennedy had previously disclosed that he might be appointed by Trump to select leaders for <a href="https://www.benzinga.com/news/24/09/40931166/robert-kennedy-jr-trump-wants-him-to-help-pick-cdc-fda-and-nih-leaders-unravel-the-capture-of-agenci">key public health agencies</a>, including the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. This latest announcement seems to confirm his involvement in these agencies, marking a significant shift in the country&#8217;s health policies.
Image via Shutterstock
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Politics

iShares Dow Jones US Pharmaceuticals Index Fund

Trump Has Asked Me To Do 3 Things, Says Robert Kennedy Jr.

Robert F. Kennedy Jr., who will meet with senior Trump aides on Wednesday to discuss his role going forward, said he would eliminate the nutrition departments at the FDA.
<a href="https://www.nbcnews.com/politics/2024-election/trump-win-rfk-jr-says-wont-take-away-anybodys-vaccines-rcna178955" title="https://www.nbcnews.com/politics/2024-election/trump-win-rfk-jr-says-wont-take-away-anybodys-vaccines-rcna178955">https://www.nbcnews.com/politics/2024-election/trump-win-rfk-jr-says-wont-take-away-anybodys-vaccines-rcna178955</a>

'After Trump win, RFK Jr. says he won't 'take away anybody's vaccines'' - NBC News

Investors with a lot of money to spend have taken a bearish stance on Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MRNA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 11 uncommon options trades for Moderna.
This isn't normal.
The overall sentiment of these big-money traders is split between 36% bullish and 54%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $214,735, and 7 are calls, for a total amount of $478,040.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $40.0 to $130.0 for Moderna over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Moderna's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Moderna's whale activity within a strike price range from $40.0 to $130.0 in the last 30 days. 
<h3>Moderna Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730907065_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$1.31</td>
<td>$1.27</td>
<td>$1.31</td>
<td>$60.00</td>
<td>$107.5K</td>
<td>2.9K</td>
<td>1.6K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$3.55</td>
<td>$3.35</td>
<td>$3.35</td>
<td>$50.00</td>
<td>$105.8K</td>
<td>4.7K</td>
<td>513</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$16.7</td>
<td>$16.65</td>
<td>$16.65</td>
<td>$40.00</td>
<td>$88.2K</td>
<td>40</td>
<td>150</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$17.0</td>
<td>$16.65</td>
<td>$16.65</td>
<td>$40.00</td>
<td>$78.2K</td>
<td>40</td>
<td>97</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$17.4</td>
<td>$16.65</td>
<td>$16.65</td>
<td>$40.00</td>
<td>$73.2K</td>
<td>40</td>
<td>50</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
<h3>Where Is Moderna Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 3,021,467, with MRNA's price down by -1.31%, positioned at $52.59.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 1 days.</li>
</ul>
<h3>Professional Analyst Ratings for Moderna</h3>
A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $69.25.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Bernstein has revised its rating downward to Market Perform, adjusting the price target to $55. 
&#x2A; An analyst from UBS persists with their Buy rating on Moderna, maintaining a target price of $108. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Underweight rating for Moderna, targeting a price of $59. 
&#x2A; Consistent in their evaluation, an analyst from Jefferies keeps a Hold rating on Moderna with a target price of $55. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Moderna Options Trading: A Deep Dive into Market Sentiment

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALLK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.00</td>
<td>$44.7K</td>
<td>552</td>
<td>2.3K</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$19.00</td>
<td>$57.0K</td>
<td>804</td>
<td>1.7K</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$45.00</td>
<td>$40.6K</td>
<td>292</td>
<td>866</td>
</tr>
<tr>
<td>ZTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$210.00</td>
<td>$32.3K</td>
<td>1.6K</td>
<td>719</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$120.00</td>
<td>$142.8K</td>
<td>2.9K</td>
<td>504</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$800.00</td>
<td>$26.5K</td>
<td>379</td>
<td>274</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$50.00</td>
<td>$232.6K</td>
<td>1.5K</td>
<td>235</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$65.00</td>
<td>$55.0K</td>
<td>368</td>
<td>155</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$285.00</td>
<td>$34.5K</td>
<td>428</td>
<td>155</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$365.00</td>
<td>$53.5K</td>
<td>215</td>
<td>108</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding ALLK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLK#NASDAQ">ALLK</a>), we observe a call option sweep with bullish sentiment. It expires in 45 day(s) on December 20, 2024. Parties traded 819 contract(s) at a $1.00 strike. This particular call needed to be split into 23 different trades to become filled. The total cost received by the writing party (or parties) was $44.7K, with a price of $55.0 per contract. There were 552 open contracts at this strike prior to today, and today 2319 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a put option sweep that happens to be bearish, expiring in 73 day(s) on January 17, 2025. This event was a transfer of 300 contract(s) at a $19.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $57.0K, with a price of $190.0 per contract. There were 804 open contracts at this strike prior to today, and today 1754 contract(s) were bought and sold. 
• Regarding TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we observe a call option sweep with bullish sentiment. It expires in 437 day(s) on January 16, 2026. Parties traded 58 contract(s) at a $45.00 strike. This particular call needed to be split into 23 different trades to become filled. The total cost received by the writing party (or parties) was $40.6K, with a price of $700.0 per contract. There were 292 open contracts at this strike prior to today, and today 866 contract(s) were bought and sold. 
• Regarding ZTS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), we observe a call option sweep with bearish sentiment. It expires in 73 day(s) on January 17, 2025. Parties traded 719 contract(s) at a $210.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $32.3K, with a price of $45.0 per contract. There were 1601 open contracts at this strike prior to today, and today 719 contract(s) were bought and sold. 
• For NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we notice a call option sweep that happens to be bearish, expiring in 73 day(s) on January 17, 2025. This event was a transfer of 340 contract(s) at a $120.00 strike. This particular call needed to be split into 24 different trades to become filled. The total cost received by the writing party (or parties) was $142.8K, with a price of $420.0 per contract. There were 2969 open contracts at this strike prior to today, and today 504 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option sweep with bullish sentiment. It expires in 10 day(s) on November 15, 2024. Parties traded 15 contract(s) at a $800.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $26.5K, with a price of $1773.0 per contract. There were 379 open contracts at this strike prior to today, and today 274 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a call option sweep with bullish sentiment. It expires in 437 day(s) on January 16, 2026. Parties traded 227 contract(s) at a $50.00 strike. This particular call needed to be split into 35 different trades to become filled. The total cost received by the writing party (or parties) was $232.6K, with a price of $1025.0 per contract. There were 1525 open contracts at this strike prior to today, and today 235 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a call option sweep with bullish sentiment. It expires in 163 day(s) on April 17, 2025. Parties traded 77 contract(s) at a $65.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $55.0K, with a price of $715.0 per contract. There were 368 open contracts at this strike prior to today, and today 155 contract(s) were bought and sold. 
• For HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we notice a call option trade that happens to be bearish, expiring in 10 day(s) on November 15, 2024. This event was a transfer of 75 contract(s) at a $285.00 strike. The total cost received by the writing party (or parties) was $34.5K, with a price of $460.0 per contract. There were 428 open contracts at this strike prior to today, and today 155 contract(s) were bought and sold. 
• For AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we notice a call option sweep that happens to be bullish, expiring in 73 day(s) on January 17, 2025. This event was a transfer of 104 contract(s) at a $365.00 strike. This particular call needed to be split into 28 different trades to become filled. The total cost received by the writing party (or parties) was $53.5K, with a price of $515.0 per contract. There were 215 open contracts at this strike prior to today, and today 108 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLK

AMGN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

10 Health Care Stocks Whale Activity In Today's Session

<a href="https://news.bloomberglaw.com/esg/modernas-bancel-steps-down-as-sales-chief-keeps-ceo-role">https://news.bloomberglaw.com/esg/modernas-bancel-steps-down-as-sales-chief-keeps-ceo-role</a>
Stephane Bancel is stepping down as chief commercial officer of Moderna Inc., according to a person familiar with the matter. He will remain in his role of chief executive officer of the biotech company.
Moderna President Stephen Hoge will assume responsibility of sales as well as medical and research affairs, according to the person who was not authorized to speak publicly.
Bancel had assumed oversight of sales and marketing after the company announced in December that Arpa Garay was leaving the company.

Management

'Moderna's Bancel Steps Down As Sales Chief, Keeps CEO Role' - Bloomberg Law

Pre-clinical data demonstrate robust anti-tumor activity and a novel off-the-shelf approach for GPC3+ solid tumors
PHILADELPHIA, Nov. 5, 2024 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4294446-1&amp;h=945549291&amp;u=https%3A%2F%2Fcarismatx.com%2F&amp;a=Carisma+Therapeutics+Inc.">Carisma Therapeutics Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the upcoming presentation of new pre-clinical data on its anti-GPC3&nbsp;in vivo&nbsp;chimeric antigen receptor macrophage and monocyte (together, "CAR-M")&nbsp;therapy for the treatment of hepatocellular carcinoma ("HCC"), developed in collaboration with Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>). The data will be presented in a poster session at the Society for Immunotherapy of Cancer ("SITC") Annual Meeting in Houston, Texas, on November 8, 2024.

CARM

Carisma Therapeutics To Present New Data On Anti-GPC3 In Vivo CAR-M Therapy For Hepatocellular Carcinoma At SITC 2024

https://www.reuters.com/world/uk/uk-detects-two-more-cases-new-mpox-variant-2024-11-04/#:~:text=LONDON%2C%20Nov%204%20(Reuters),to%20the%20population%20remained%20low.

Macro Notification

AEMD

CMRX

GOVX

TNXP

VRAX

'UK detects two more cases of new mpox variant' - Reuters

Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) has outperformed the market over the past 5 years by 12.29% on an annualized basis producing an average annual return of 25.34%. Currently, Moderna has a market capitalization of $20.80 billion. 
Buying $100 In MRNA: If an investor had bought $100 of MRNA stock 5 years ago, it would be worth $309.19 today based on a price of $54.11 for MRNA at the time of writing.
<h3>Moderna's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730745010_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today

In the latest quarter, 15 analysts provided ratings for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $85.4, a high estimate of $139.00, and a low estimate of $55.00. A decline of 22.58% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1730732735_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Moderna. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$59.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$108.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Courtney Breen</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Yee</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$55.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$139.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$110.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Tyler Van Buren</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$60.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$75.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$70.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Michael Yee</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$65.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Yifeng Liu</td>
<td>HSBC</td>
<td>Announces</td>
<td>Hold</td>
<td>$82.00</td>
<td>-</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$88.00</td>
<td>$96.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Moderna. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Moderna compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Moderna's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Moderna's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MRNA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Moderna analyst ratings.</a>
<h2>About Moderna</h2>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
<h3>Breaking Down Moderna's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Moderna's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -30.06%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Moderna's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -578.73%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Moderna's ROE excels beyond industry benchmarks, reaching -10.43%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -7.89%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Moderna's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.11.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Examination Of 15 Analyst Recommendations For Moderna

JP Morgan analyst Jessica Fye maintains Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Underweight and lowers the price target from $70 to $59.

JP Morgan Maintains Underweight on Moderna, Lowers Price Target to $59

The stock market indexes have enjoyed record highs in recent years with the S&amp;P 500 outperforming other years with President Joe Biden leading the country for the last <a href="https://www.benzinga.com/general/education/24/02/37275812/if-you-invested-in-the-s-p-500-when-joe-biden-became-president-heres-how-much-youd-have-today">nearly four years.</a>
With the 2024 presidential election nearing, here's a look back at the top performing S&amp;P 500 stocks in 2021, which was Biden's first year in the White House.
What Happened: Biden stepped down from <a href="https://www.benzinga.com/topic/2024-election">the 2024 presidential election </a>earlier this year. While the current president won't be re-elected to the White House, past performance with a Democrat as president could highlight which stocks and sectors could be winners if Kamala Harris is victorious in Tuesday's election.
The S&amp;P 500, which is tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 26.9% in 2021. This marked the best yearly performance since 2018 and the second-best performance for the key stock market index in the last 11 years.
The 12 months following Election Day 2020, which was won by Biden, <a href="https://www.benzinga.com/news/22/01/25137004/biden-vs-trump-how-did-stock-market-returns-compare-after-their-first-year-as-president">saw the S&amp;P 500 gain 37.4%.</a> This was the best one-year market return under a president in many years.
Here were the 10 best-performing S&amp;P 500 stocks in 2021, according to a <a href="https://finance.yahoo.com/news/top-10-best-performing-stocks-190949855.html">report </a>from InvestorPlace, and their sectors.
<ol>
<li>Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>): 196.1%, energy</li>
<li>Marathon Oil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRO#NYSE">MRO</a>): 149.7%, energy</li>
<li>Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>): 143.1%, health care/biotech</li>
<li>Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>): 142.0%, technology/cybersecurity</li>
<li>Signature Bank (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SBNY#OTC">SBNY</a>): 141.5%, financials</li>
<li>Ford (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>): 137.5%, automotive</li>
<li>Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>): 133.7%, consumer discretionary/retail</li>
<li>Diamondback Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>): 127.4%, energy</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>): 125.5%, technology/semiconductors</li>
<li>Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>): 118.4%, industrials</li>
</ol>
The results above show that energy was a top sector in 2021 and represented several of the top-performing stocks for the year. Technology also had several companies on the list.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent103124">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: Click through <a href="https://www.benzinga.com/general/politics/24/10/41584466/these-10-stocks-were-the-best-s-p-500-performers-in-2017-when-trump-was-president-will-history-r">to see the 10 best</a> and <a href="https://www.benzinga.com/general/politics/24/10/41606114/10-s-p-500-stocks-were-worst-performers-in-first-year-of-trumps-presidency-will-they-sink-again">10 worst-performing</a> S&amp;P 500 stocks of 2017, Donald Trump's first year in the White House.
The list above included Nvidia, which was also a top 10 winner in 2017, during Donald Trump's first year in the White House.
<a href="https://www.benzinga.com/topic/signature-bank" target="_blank" rel="noopener">Signature Bank</a>, which was the third-largest bank failure in U.S. history, was a top performer in 2017.
Investors should consider whether these past results could repeat if Harris is elected and begins her presidential term in 2025. Energy isn't often thought of as a segment that could do well under a Democratic president, but past results show that the sector could do well, at least in the first year.
Coincidentally, energy was cited as a potential poor sector if Trump wins the 2024 election based on the 2017 results. What likely happened in 2017, and what could happen again, is a run-up in stocks during the election year and a potential selloff in the year after as investors take profits.
With less than one week until the 2024 election, investors are likely positioning their portfolio based on a Trump or&nbsp;Harris&nbsp;victory in some regards. With a close election predicted, investors may want to look to sectors that could benefit under either candidate.
Freedom Capital Markets&nbsp;Chief Global Strategist&nbsp;Jay Woods&nbsp;previously<a href="https://www.benzinga.com/etfs/sector-etfs/24/08/40515453/exclusive-trump-or-harris-12-stocks-2-etfs-could-win-no-matter-whos-president-says-market-strate" target="_blank" rel="noreferrer noopener">&nbsp;shared some sectors&nbsp;</a>and stocks to watch with Benzinga that could benefit regardless of whether Trump or Harris wins the 2024 election.
Woods named defense stocks and cybersecurity stocks as two of the top sectors to watch ahead of the 2024 election.
&#8220;I think you&#8217;ve got to watch this sector closely,&#8221; Woods said of the defense sector.
Woods added that defense stocks could continue to benefit from geopolitical concerns and the world's many adverse events.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/sports-betting/24/10/41589659/trump-vs-harris-state-by-state-2024-election-betting-odds-which-candidate-is-favored-to-wi">Trump Vs. Harris: State-By-State 2024 Election Betting Odds, Which Candidate Is Favored To Win In Your Community?</a></li>
</ul>
Photo: Shutterstock

Education

BBWI

FANG

FTNT

NVDA

SBNY

These 10 Stocks Were S&P 500's Top Performers In Biden's First Year: Could Trend Continue If Harris Wins 2024 Election?

APDN

BWVI

WHO Expands Emergency Use List For Mpox Diagnostics, Adds Cepheid's Xpert Mpox PCR Test And Roche's Cobas MPXV Assay As PCR-Based Gold Standard Options

Deep-pocketed investors have adopted a bullish approach towards Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MRNA usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for Moderna. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 54% leaning bullish and 36% bearish. Among these notable options, 2 are puts, totaling $140,165, and 9 are calls, amounting to $365,426.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $40.0 to $75.0 for Moderna over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1456.4 with a total volume of 1,612.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Moderna's big money trades within a strike price range of $40.0 to $75.0 over the last 30 days.
<h3>Moderna Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730210475_0_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$4.85</td>
<td>$4.8</td>
<td>$4.8</td>
<td>$58.00</td>
<td>$120.0K</td>
<td style="text-align: right;">88</td>
<td style="text-align: right;">299</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$5.35</td>
<td>$5.1</td>
<td>$5.35</td>
<td>$45.00</td>
<td>$82.9K</td>
<td style="text-align: right;">276</td>
<td style="text-align: right;">301</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$5.35</td>
<td>$5.3</td>
<td>$5.3</td>
<td>$45.00</td>
<td>$57.2K</td>
<td style="text-align: right;">276</td>
<td style="text-align: right;">146</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$9.1</td>
<td>$8.7</td>
<td>$9.1</td>
<td>$50.00</td>
<td>$45.5K</td>
<td style="text-align: right;">498</td>
<td style="text-align: right;">51</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/08/24</td>
<td>$3.55</td>
<td>$3.35</td>
<td>$3.44</td>
<td>$58.00</td>
<td>$34.4K</td>
<td style="text-align: right;">311</td>
<td style="text-align: right;">103</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Following our analysis of the options activities associated with Moderna, we pivot to a closer look at the company's own performance.
<h3>Current Position of Moderna</h3>
<ul>
<li>With a trading volume of 975,484, the price of MRNA is up by 3.05%, reaching $56.47.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 9 days from now.</li>
</ul>
<h3>What The Experts Say On Moderna</h3>
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $72.66666666666667.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Jefferies continues to hold a Hold rating for Moderna, targeting a price of $55. 
&#x2A; In a cautious move, an analyst from Bernstein downgraded its rating to Market Perform, setting a price target of $55. 
&#x2A; An analyst from UBS persists with their Buy rating on Moderna, maintaining a target price of $108. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Behind the Scenes of Moderna's Latest Options Trends

On Monday, Merck&nbsp;&amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) announced the initiation of INTerpath-009, a pivotal Phase 3 trial of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41569578/merck-and-moderna-initiate-phase-3-trial-evaluating-adjuvant-v940-mrna-4157-in-combination-with-ke" rel="noreferrer noopener">V940 (mRNA-4157)</a>.
V940 is an investigational individualized neoantigen therapy under development in combination with Keytruda&nbsp;(pembrolizumab) as adjuvant treatment for resectable Stage II, IIIA or IIIB (N2) non-small cell lung cancer (NSCLC) patients who did not achieve a pathological complete response (pCR) after receiving neoadjuvant Keytruda plus platinum-based chemotherapy.
Global recruitment in INTerpath-009 has begun, and the first patients have started enrolling in Canada.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40863528/moderna-faces-analyst-downgrades-amid-revised-r-d-restructured-strategy-and-delayed" rel="noreferrer noopener">Moderna Faces Analyst Downgrades Amid Revised R&amp;D Restructured Strategy and Delayed Profitability Target</a>
Merck and Moderna have initiated Phase 3 trials evaluating mRNA-4157 (V940) in combination with Keytruda as an adjuvant treatment in patients with resected high-risk (Stage IIB-IV) melanoma (INTerpath-001) and non-small cell lung cancer (INTerpath-002).
In 2024, Merck and Moderna also initiated a two-part Phase 2/3 trial evaluating mRNA-4157 in combination with Keytruda as neoadjuvant and adjuvant treatment for resectable locally advanced Stage II-IV cutaneous squamous cell carcinoma (INTerpath-007), a Phase 2 trial of mRNA-4157 (V940) plus Keytruda as adjuvant treatment for intermediate-high-risk, high-risk, or M1 no evidence of disease renal cell carcinoma (INTerpath-004), and a Phase 2 trial of mRNA-4157 plus Keytruda as adjuvant treatment for high-risk muscle-invasive urothelial carcinoma post-radical resection (INTerpath-005).
In June, the companies unveiled the first presentation of results from a planned analysis from the Phase 2b&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/06/ac39134412/moderna-merck-announce-3-year-data-for-mrna-4157-v940-in-combination-with-keytruda-r-pembrolizuma" rel="noreferrer noopener">KEYNOTE-942/mRNA-4157-P201 study</a>.
With a median follow-up of approximately three years (34.9 months), adjuvant treatment with mRNA-4157 (V940) in combination with Keytruda continued to demonstrate a clinically meaningful and durable improvement in recurrence-free survival (RFS), the primary endpoint of the study, reducing the risk of recurrence or death by 49% <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39138772/moderna-merck-reveal-three-year-data-for-individualized-cancer-therapy-in-high-risk-melanoma-pati" rel="noreferrer noopener">compared with Keytruda alone</a>.
Price Action: MRNA stock is up 2.90% at $54.63 at last check Monday.
Photo by Lutsenko_Oleksandr on Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41580089/alibaba-becomes-key-holding-in-chinese-fund-managers-portfolio-economic-measures-spark-interest-in-l" target="_blank" rel="noreferrer noopener">Alibaba Becomes Key Holding in Chinese Fund Manager&#8217;s Portfolio, Economic Measures Spark Interest in Leading Tech</a></li>
</ul>

Large Cap

Why Is Moderna Stock Trading Higher On Monday?

How is QQQ stock faring? The Invesco QQQ ETF is up 1.2% in the past five days and has risen about 19.19% year-to-date. &nbsp; According to TipRanks...

QQQ ETF Update, 11/6/2024

Notable companies reporting before tomorrow's open, with earnings consensus, include Transdigm (TDG), consensus $9.32… Becton Dickinson (BDX), cons...

Notable companies reporting before tomorrow's open

Moderna Q3 2024 Preview: Revenue to fall due to continued COVID market share decline

How is SPY stock faring? The SPDR S&P 500 ETF Trust&nbsp;is up 3.67% in the past five days and has risen 33.77% over the past year. According to Ti...

SPY ETF Update, 11/7/2024

Moderna beats Q3 top and bottom line estimates

Today, several major companies are expected to report earnings: Barrick Gold (GOLD), Block (SQ), Trade Desk (TTD), Moderna (MRNA), Pinterest (PINS)...

Options Volatility and Implied Earnings Moves Today, November 07, 2024

Moderna swings to profits as new COVID shot powers Q3 beat

Moderna, Inc. 2024 Q3 - Results - Earnings Call Presentation

4 stocks to watch on Thursday: ABNB, RIVN and more

Unusual total active option classes on open include: Aurinia Pharmaceuticals (AUPH), Baxter (BAX), Chevron (CVX), Warner Bros. Discovery (WBD), Dat...

Unusually active option classes on open November 7th

ABNB

APTV

AUPH

BIIB

DDOG

DKNG

ELAN

GDRX

GILD

GOLD

GRMN

KVUE

MBLY

ODFL

PAYC

PAYX

PENN

PINS

PLNT

PLTK

PLTR

PZZA

RIVN

SMCI

TSLA

USFD

VALE

YETI

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation

Screenshot 2024-03-13 at 5.45.52 PM

FDXTF

SHTDY

Nanotechnology&#39;s Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX&#39;s Nanotechnology

Press Releases

MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Legal

The Gross Law Firm Notifies Moderna, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – MRNA

Flagship Pioneering Announces Appointment of Paul Parker as Managing Partner, Leading Capital Solutions

Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024

Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence

Moderna Named a Top Employer by Science for Tenth Consecutive Year

Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)

Moderna to Present at Upcoming Conferences in November 2024

Penny Stocks

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024

Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates

Comments

Moderna

Moderna (MRNA) Opciones

Moderna (NASDAQ:MRNA) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL